CalciMedica(CALC) - 2024 Q2 - Quarterly Results

Exhibit 99.1 CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., August 12, 2024 – CalciMedica Inc. ("CalciMedica or the Company") (Nasdaq: CALC), a clinic ...